Skip to main content
Equibles
ARQT logo

ARQT · Arcutis Biotherapeutics, Inc.

Track ARQT — free

Use ARQT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$23.90 +0.24 (+1.01%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$2.97B
Shares
125.69M

ARQT metrics

76 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.90
Market cap
$2.97B

Price action

19 metrics
Price change (1W)
+0.5%
Price change (30D)
-9.6%
Price change (3M)
+12.6%
Price change (6M)
-0.4%
Price change (YTD)
-17.7%
Price change (1Y)
+47.4%
Trailing year
Price change (5Y)
+10.4%
52-week high
$31.20
52-week low
$16.21
Change from 52-week high
-23.4%
Change from 52-week low
+47.4%
Annualized volatility
56.2%
Beta
1.1
RSI (14D)
38.1
Price vs SMA 50
-9.4%
Price vs SMA 200
-6.7%
Avg volume (3M)
1.67M
Relative volume
1.0
Average dollar volume
$43.48M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
125.69M

Valuation

12 metrics
P / E (TTM)
108.6
Trailing earnings · reciprocal yield 0.9%
PEG ratio
—
EV / revenue
6.6×
reciprocal yield 15.3%
EV / EBITDA
—
EV / EBIT
88.8×
reciprocal yield 1.1%
P / sales
6.4×
reciprocal yield 15.6%
P / book
13.5
reciprocal yield 7.4%
FCF yield
1.3%
TTM · current market cap
Buyback yield
—
P / FCF
75.8
reciprocal yield 1.3%
P / operating cash flow
75.5
reciprocal yield 1.3%
Earnings yield
1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.7×
reciprocal yield 7.3%
EV / revenue historical average (5Y)
13.7×
reciprocal yield 7.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
91.1%
Operating margin
7.4%
Trailing 12 months
Net margin
6.1%
Gross profit (TTM)
—
Operating profit (TTM)
$34.25M
Net income (TTM)
$28.52M
Trailing 12 months
Diluted EPS (TTM)
$0.22
FCF margin
8.4%
Effective tax rate
2.7%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-30.66

Growth

11 metrics
Revenue growth YoY
+59.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$463.98M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.0%
Year over year · more shares
Revenue CAGR (3Y)
+367.3%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
12.9%
Return on assets
5.8%
Debt / equity
0.5
Current ratio
2.9
EBITDA (TTM)
—
Free cash flow (TTM)
$39.15M
Quick ratio
2.7
Interest coverage
2.5
Net debt / EBITDA
—
Return on invested capital
11.3%
Trailing 12 months
Net cash
−$74.78M
Latest balance sheet
Cash & equivalents
$34.12M
Total assets
$488.54M
Total debt
$108.90M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$39.31M
Capital expenditures (TTM)
$158,000
R&D (TTM)
$91.04M
SG&A (TTM)
$297.60M
Stock compensation (TTM)
$43.55M
R&D / revenue
19.6%
Stock compensation / revenue
9.4%

Ownership (13F)

3 metrics
13F filers
271
13F filer change QoQ
+1
Institutional ownership
105.0%

Short interest

3 metrics
Short interest
11.7%
Latest settlement · 8.0 days to cover
Days to cover
8.0d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$2.08M
Insider-sentiment score
28 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1787306 CUSIP 03969K108 13F (30d) 213 filings 209 filers Visit website Investor relations